We’re excited to share that Merck’s new monoclonal antibody, Enflonsia™, is now part of the CPP portfolio. This addition reflects the latest recommendation from the Advisory Committee on Immunization Practices (ACIP) for the prevention of respiratory syncytial virus (RSV) in infants.
What is Enflonsia™?
Enflonsia™ is a single-dose monoclonal antibody designed to protect infants younger than 8 months who are born during or entering their first RSV season. Unlike weight-based dosing, Enflonsia™ is administered as a standard 0.7 mL intramuscular injection, simplifying administration protocols. Click here for more information on Merck’s Enflonsia™
- Billing Information
Enflonsia™ is billed under CPT code 90382: Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use.
CPP recommends that practices check with major payers to confirm coverage and reimbursement before adding new immunizations to your schedule. Typically, payment begins approximately 90 days after the CDC Director affirms ACIP’s recommendation.
CPP Member Benefits
CPP is offering a discount to those members already participating in the CPP/Merck contract. If your practice is not yet enrolled in the CPP/Merck discount program or if you’d like updated pricing, please reach out to the CPP office at cpp@nationwidechildrens.org.
